Shanghai Children's Medical Center: A National Hub for Pediatric Hematology & Oncology
Lead unit of the National Children's Medical Center Hematology/Oncology Specialty Alliance and a Shanghai key discipline. The first pediatric HSCT team in Shanghai, performing 260+ transplants annually (~3,000 cumulative) with a 97% engraftment success rate, and home to China's first SCID and MPS VI transplants.
What matters most on this page
Short answer:Lead unit of the National Children's Medical Center Hematology/Oncology Specialty Alliance and a Shanghai key discipline. The first pediatric HSCT team in Shanghai, performing 260+ transplants annually (~3,000 cumulative) with a 97% engraftment success rate, and home to China's first SCID and MPS VI transplants.
Key points
- Lead Unit — National Children's Medical Center Hem/Onc Alliance
- 260+ Transplants Annually · ~3,000 Cumulative
- Engraftment Success Rate 97%
- China's First SCID and MPS VI Transplants
If your child has been diagnosed with a blood disorder or a malignant tumor, the Department of Hematology & Oncology at Shanghai Children's Medical Center (SCMC) is one of China's most trusted destinations for pediatric care.
SCMC is a Grade 3A (top-tier) children's hospital in Pudong, Shanghai, jointly developed by the Shanghai Municipal Government and Project HOPE. It opened in June 1998. The Department of Hematology & Oncology is one of the hospital's flagship specialties, operating within the Pediatric Hematology & Oncology Research Center of Shanghai Jiao Tong University School of Medicine.
At Medora, we help international families navigate SCMC's pediatric hematology-oncology team. Here's what you need to know.
History
- 1970: The department traces its origins to Xin Hua Hospital of the former Shanghai Second Medical University — among the earliest pediatric hematology/oncology programs established in China.
- Built up by pioneering experts Xie Jingxiong, Ying Daming, Wang Yaoping, and Gu Longjun, the department has grown into a leading pediatric hematology-oncology center in China.
- It is the lead unit of the National Children's Medical Center Hematology/Oncology Specialty Alliance and a Shanghai key discipline in pediatric hematology/oncology.
Core Expertise and Technologies
- Pediatric HSCT: Founded Shanghai's first pediatric HSCT team in 2000; completed China's first transplant for congenital immunodeficiency (2005), first mucopolysaccharidosis type VI transplant (2006), and first SCID transplant (2008).
- Unrelated HLA-mismatched transplantation: among the first in China, filling a national gap in HLA compatibility research.
- CD34+ purified transplantation: an early adopter, improving outcomes in neuroblastoma.
- Aplastic anemia transplantation: innovative conditioning regimens achieving internationally leading results; co-founded the Viva–St. Jude Asia-Pacific pediatric aplastic anemia transplant collaborative group in 2014.
- Molecular diagnostics for hereditary blood diseases: built China's first dedicated platform, identifying over 200 rare blood disorders.
- CAR-T cell therapy: applied to refractory/relapsed acute lymphoblastic leukemia.
Expert Team
| Expert | Title | Specialty |
|---|---|---|
| Chen Jing | Chief Physician, Doctoral Supervisor, Second-Class Professor | Director of the Hematology & Oncology Department and of the SCMC Rare Disease Center; discipline leader and chief expert in HSCT; Chair of the National Children's Medical Center Hematology/Oncology Specialty Alliance, Executive Deputy Director of the NHC Children's Leukemia Expert Committee, Deputy Head of the CMA Pediatric Hematology Group, Vice President of the Asia-Pacific pediatric transplant society |
| Tang Jingyan | Chief Physician, Professor, Doctoral Supervisor | Chair of the Chinese Pediatric Tumor Committee |
| Gu Longjun | Chief Physician | Shanghai key-discipline leader in pediatric hematology/oncology; author of over 250 papers |
| Xue Huiliang, Shen Shuhong | Chief Physicians | Pediatric hematology and oncology |
| Pan Ci | Associate Chief Physician | Pediatric malignant solid tumors and hematologic malignancies |
Clinical Scale and Outcomes
- By June 30, 2018, the department had performed 1,217 HSCTs (1,011 allogeneic and 206 autologous), making it one of the largest pediatric allogeneic HSCT centers in China at that time.
- Allogeneic transplant case mix: 457 malignant hematologic diseases, 312 aplastic anemia, and 212 rare diseases.
- Overall engraftment success rate: 97%; 5-year overall survival of allogeneic transplants: 65%; 5-year overall survival for benign diseases: 83%.
- According to more recent hospital data, the team performs over 260 transplants annually, with a cumulative total approaching 3,000.
Honors
- Lead unit of the National Children's Medical Center Hematology/Oncology Specialty Alliance.
- Historically ranked first among children's hospitals in China for transplant case volume and disease diversity.
- The team has received the Shanghai Science & Technology Progress Award, the Chinese Anti-Cancer Association Science & Technology Award, the Huaxia Medical Award, and the Soong Ching Ling Pediatric Medicine Award. Prof. Chen Jing has published over 100 first/corresponding-author papers, including in Cancer Cell.
Address and Contact
- Main campus: 1678 Dongfang Road, Pudong New Area, Shanghai
- Zhangjiang campus: 161 Tianniu Road, Pudong New Area, Shanghai
- Transport: Metro Line 6, "Shanghai Children's Medical Center" station (about a 1-minute walk from Exit 3, Dongfang Road)
- Phone: 021-38626161 (appointments)
This guide is prepared for an international audience. If you need assistance with medical consultation, appointment booking, or travel arrangements to Shanghai Children's Medical Center's Department of Hematology & Oncology, contact Medora for personalized support.
Need personalized hospital recommendations?
Turn this research into an action plan: get tailored hospital recommendations matched to your condition, budget, and timeline.
✓ Free consultation · Response within 24 hours · 100+ international patients served